Analysis: Might be too early to talk Encysive buyout

06/26/2007 | TheStreet.com

Encysive Pharmaceuticals is undergoing a major shakeup, replacing its CEO, laying off 70% of the work force and cutting its expenses. The restructuring was undertaken following the company's failure to get approval for its pulmonary hypertension drug, Thelin. There are questions whether Thelin is currently valuable enough to attract suitors to Encysive if the board puts the company up for sale.

View Full Article in:

TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC